FDA sets May 1 deadline for UniQure's Huntington's gene therapy; Inovio's Voceryq approved for RRP; AbbVie wins Botox IRA ...
AbbVie licenses two preclinical migraine programs from China’s Brise Pharmaceuticals in a $757M deal that dates back to 2024.
Fresenius gets exclusive options on up to 37 WuXi Biologics biosimilar candidates, potentially more than doubling its 29-molecule portfolio.
Karyopharm files for Chapter 11 and plans a merger with Gamida Cell parent Ayrmid, backed by $55M in DIP financing; shares fall 84%.
Regulators issued the hold for Bright Minds' BMB-101 after identifying toxicity issues in preclinical mouse models.
Hello and welcome back to a spooky Halloween edition of Endpoints Weekly! Sorry to all the candy corn lovers out there, but ...
Plowshare Therapies, led by Kevin Strauss, aims to develop a gene therapy for maple syrup urine disease, targeting ...
Bristol Myers touts 7% Q3 revenue growth and admilparant progress as it faces 2028 patent cliffs for Eliquis and Opdivo.
Pfizer’s flood-damaged Gujarat cancer drug plant won’t resupply until 2028, deepening US chemotherapy shortages, ASHP said.
Anthropic buys Mithril Medicine, a one-person stealth biotech backed by Atlas whose founder ran the “Professor Oak” account ...
AstraZeneca launches a restructuring to save $1.5B a year for R&D, beats Q3 sales forecasts and cuts several trials, ...
Gilead pauses KITE-753 trials over ICANS; Agios' mitapivat PDUFA delayed; Acumen scraps sabirnetug; BMS drops BMS-986495; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results